Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Constipation

Interventions

DRUG: SP-333 1 mg
DRUG: SP-333 3 mg
DRUG: SP-333 6 mg
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.